Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Hypoxia

erlotinib hydrochloride has been researched along with Hypoxia in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (71.43)24.3611
2020's2 (28.57)2.80

Authors

AuthorsStudies
Berger, W; Caban, M; Groza, D; Heffeter, P; Jaunecker, C; Keppler, BK; Koblmueller, B; Kowol, CR; Kryeziu, K; Mathuber, M; Mohr, T; Pirker, C; Schueffl, HH; Terenzi, A; Tolios, A1
Li, G; Sai, B; Tang, J; Wang, F; Wang, L; Xiang, J; Zhang, L; Zhang, X; Zheng, L1
Gao, Y; Jia, L; Li, F; Li, T; Mei, H; Nie, H; Xie, X; Zhang, H1
Hebisawa, A; Hirose, T; Kitani, M; Kusaka, K; Matsui, H; Miyakawa, K; Ohta, K; Shimada, M; Tamura, A; Yokoyama, A1
Li, W; Zhou, Y1
Baty, F; Betticher, D; Brutsche, MH; Droege, C; Dürr, O; Franzini, A; Grigoriu, BD; Klingbiel, D; Macovei, II; Zappa, F1
Foo, J; Garvey, CM; Lindsay, D; Mumenthaler, SM1

Other Studies

7 other study(ies) available for erlotinib hydrochloride and Hypoxia

ArticleYear
A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
    Cancer letters, 2023, 07-01, Volume: 565

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hypoxia; Lung Neoplasms; Prodrugs; Protein Kinase Inhibitors

2023
BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment.
    Cancer biology & therapy, 2020, Volume: 21, Issue:1

    Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Marrow; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Insulin-Like Growth Factor Binding Protein 2; Leptin; Lung Neoplasms; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Receptor, IGF Type 1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays

2020
Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer.
    Biomaterials, 2017, Volume: 145

    Topics: Animals; Aptamers, Nucleotide; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Endocytosis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hypoxia; Immunohistochemistry; Liposomes; Lung Neoplasms; Mice, Nude; Models, Biological; Oxygen; Tissue Distribution

2017
Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.
    Internal medicine (Tokyo, Japan), 2018, Aug-15, Volume: 57, Issue:16

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adrenal Cortex Hormones; Anaplastic Lymphoma Kinase; Carbazoles; Cough; ErbB Receptors; Erlotinib Hydrochloride; Female; Fever; Humans; Hypoxia; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Receptor Protein-Tyrosine Kinases; Treatment Outcome

2018
LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial-mesenchymal transition.
    Bioscience reports, 2019, 01-31, Volume: 39, Issue:1

    Topics: Cadherins; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hypoxia; MAP Kinase Signaling System; Melanoma; Membrane Glycoproteins; Neoplasm Invasiveness; Neovascularization, Pathologic; Up-Regulation

2019
Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Dec-01, Volume: 21, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Humans; Hypoxia; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Reproducibility of Results; Transcriptome; Treatment Outcome

2015
Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.
    PLoS computational biology, 2016, Volume: 12, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Hypoxia; Lung Neoplasms; Prodrugs; Tumor Microenvironment

2016